Related Experiment Video

Updated: May 6, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
09:06

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method

Published on: October 7, 2025

563

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises

D Cortinovis, V Monica, F Pietrantonio

  • 1Oncology Unit, San Gerardo Hospital, Monza. d.cortinovis@hsgerardo.org.

Current Pharmaceutical Design
|October 22, 2013
PubMed

Insights

Tumor biological characterization is crucial for non-small cell lung cancer (NSCLC) patients. MicroRNA (miRNA) profiling shows potential for predicting recurrence, guiding targeted therapies, and determining prognosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Tumor biological characterization is essential for non-small cell lung cancer (NSCLC) patients, aiding in identifying high-risk recurrence cases and guiding targeted therapies (e.g., EGFR, ALK inhibitors).
  • Molecular parameters show promise in predicting the efficacy of systemic cytotoxic therapy in NSCLC.
  • MicroRNAs (miRNAs), small non-coding RNA molecules, regulate gene expression post-transcriptionally and are increasingly implicated in various human cancers.

Purpose of the Study:

  • To review the current literature on the role of microRNAs (miRNAs) in non-small cell lung cancer (NSCLC).
  • To summarize the potential of miRNA profiling for differentiating tumor subtypes, determining prognosis, and predicting response to therapy in NSCLC.

Main Methods:

  • Literature review of current research on microRNAs in NSCLC.
  • Analysis of studies investigating miRNA expression in relation to cancer carcinogenesis, progression, and therapeutic response.

Main Results:

  • Aberrant miRNA expression is frequently observed in human cancers, including NSCLC, and plays a significant role in cancer development and progression.
  • Emerging evidence suggests that miRNA profiling can accurately differentiate tumor subtypes and predict patient prognosis.
  • miRNA signatures are being explored for their utility in predicting the effectiveness of both targeted therapies and systemic cytotoxic treatments in NSCLC.

Conclusions:

  • MicroRNA profiling represents a promising and rapidly evolving field with significant potential for personalized medicine in NSCLC.
  • Further research into miRNA biomarkers could enhance diagnostic accuracy, prognostic prediction, and therapeutic strategy selection for NSCLC patients.

More Related Videos

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

6.8K
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

17.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.1K
MicroRNAs01:22

MicroRNAs

9.8K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
7.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K